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Targeted suppression of 
autoreactive CD8+ T-cell activation 
using blocking anti-CD8 antibodies
Mathew Clement1, James A. Pearson1, Stephanie Gras2,3, Hugo A. van den Berg4, 
Anya Lissina5, Sian Llewellyn-Lacey1, Mark D. Willis6, Tamsin Dockree1, James E. McLaren1, 
Julia Ekeruche-Makinde7, Emma Gostick1, Neil P. Robertson6, Jamie Rossjohn1,2,3, 
Scott R. Burrows8, David A. Price1,9, F. Susan Wong1, Mark Peakman10,*, Ania Skowera10,* & 
Linda Wooldridge5,*
CD8+ T-cells play a role in the pathogenesis of autoimmune diseases such as multiple sclerosis and type 
1 diabetes. However, drugs that target the entire CD8+ T-cell population are not desirable because 
the associated lack of specificity can lead to unwanted consequences, most notably an enhanced 
susceptibility to infection. Here, we show that autoreactive CD8+ T-cells are highly dependent on CD8 
for ligand-induced activation via the T-cell receptor (TCR). In contrast, pathogen-specific CD8+ T-cells are 
relatively CD8-independent. These generic differences relate to an intrinsic dichotomy that segregates 
self-derived and exogenous antigen-specific TCRs according to the monomeric interaction affinity 
with cognate peptide-major histocompatibility complex class I (pMHCI). As a consequence, “blocking” 
anti-CD8 antibodies can suppress autoreactive CD8+ T-cell activation in a relatively selective manner. 
These findings provide a rational basis for the development and in vivo assessment of novel therapeutic 
strategies that preferentially target disease-relevant autoimmune responses within the CD8+ T-cell 
compartment.
CD8+ T-cells recognise cognate peptide-major histocompatibility complex class I (pMHCI) antigens via the 
clonotypically-expressed α β T-cell receptor (TCR) and the lineage-specific CD8 coreceptor1,2. The TCR engages 
the α 1/α 2 domain peptide-binding platform of pMHCI, thereby dictating antigen specificity3. In contrast, CD8 
binds at a spatially distinct and largely conserved site formed by the α 3 domain of the MHCI heavy chain with 
a contribution from β 2-microglobulin, an event that acts functionally to enhance antigen sensitivity4,5. Several 
mechanisms are involved in this latter phenomenon, including: (i) stabilisation of the TCR/pMHCI interaction6,7; 
(ii) recruitment of essential signalling molecules to the intracellular side of the TCR/CD3/ζ complex8–11; and (iii) 
localisation of the TCR/pMHCI complex within membrane micro-domains that form privileged sites for the 
initiation of TCR-mediated signalling12,13. This allows the CD8 coreceptor to fine-tune antigen-specific responses 
within the CD8+ T-cell compartment.
It has become increasingly evident in recent years that CD8+ T-cells play a key role in the pathogene-
sis of autoimmune diseases such as type 1 diabetes (T1D)14–16 and multiple sclerosis (MS)17–19. As such, there 
is a strong rationale for developing therapeutic strategies that target the autoreactive CD8+ T-cell popula-
tion20–22. Previous studies have employed antibodies directed against T-cell surface markers (CD3, CD4 and 
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CD8) to induce tolerance in mice20,21,23,24, although to date, it has not been possible to translate strategies using 
“tolerance-inducing antibodies” into humans25. However, there are important biological differences between 
autoreactive and pathogen-specific CD8+ T-cells that may be amenable to therapeutic exploitation. Extensive 
biophysical analyses have shown that pathogen-specific TCRs typically engage cognate pMHCI with high mon-
omeric affinities (range KD ~1–50 μ M)3,26. In contrast, autoreactive TCRs that escape negative selection display 
markedly lower monomeric affinities for pMHCI (KD > 100 μ M)27–30. Autoimmune disease-relevant TCR/pMHCI 
interactions may even occur at KD values > 200 μ M31,32. Importantly, CD8+ T-cells bearing such low affinity TCRs 
are highly dependent on CD8 for cognate ligand-induced activation33,34. On the basis of these observations, we 
hypothesised that CD8-targeted strategies could be used to inhibit autoreactive CD8+ T-cells in a relatively selec-
tive manner.
Anti-CD8 monoclonal antibodies have been used widely to study the functional role of the CD8 core-
ceptor35,36. To phenotype such antibodies we have defined the following criteria: (1) effect on pMHCI tetramer 
staining, (2) effect on pMHCI specific activation; and, (3) ability to trigger non-specific activation (i.e. to elicit 
effector function in the absence of TCR/pMHCI engagement)37. We have observed that considerable hetero-
geneity exists between different anti-CD8 antibodies. In general, anti-CD8 antibodies can inhibit or enhance 
pMHCI tetramer binding, which is mirrored by their effect on pMHCI antigen-specific activation35. It is notable 
that the anti-mouse CD8 antibody YTS105.18 has been used in previous studies to reverse T1D in non-obese 
diabetic (NOD) mice20,21. This clone does not inhibit pMHCI binding or antigen-specific CD8+ T-cell activation 
and therefore cannot be classified as a “blocking” antibody38. In contrast, we have selected an anti-human CD8 
antibody (DK25) that exhibits a potent blocking phenotype. DK25 inhibits pMHCI tetramer binding at the cell 
surface, inhibits pMHCI antigen specific T-cell activation but does not trigger non-specific activation35,37.
We show that autoreactive CD8+ T-cells are preferentially inhibited by blocking anti-CD8 antibodies as a 
consequence of low affinity TCR/pMHCI interactions that confer an intrinsic dependence on the CD8 coreceptor 
for ligand-induced activation via the TCR. Our findings suggest novel strategies for the treatment of autoimmune 
diseases without the attendant side effects that complicate generalised immunosuppression.
Results
Autoreactive CD8+ T-cells expressing low affinity TCRs are highly CD8-dependent. A primary 
aim of this study was to test the hypothesis that autoreactive CD8+ T-cells are highly dependent on CD8 for 
ligand-induced activation via the TCR. In preliminary experiments, we made use of the well-characterised CD8+ 
T-cell clone 1E6, which is specific for the HLA-A*0201-restricted preproinsulin (PPI) epitope ALWGPDPAAA 
(ALW)39. Despite a low affinity monomeric interaction between the 1E6 TCR and cognate pMHCI (KD = 278 μ M), 
this clone recognises and destroys human pancreatic β -cells in vitro32,39. To examine the CD8 dependency of 
1E6, we measured effector outputs in response to titrated doses of the cognate peptide ligand presented by C1R-
A*0201 or C1R-A*0201 D227K/T228A cells. In the absence of pMHCI/CD8 engagement due to the HLA-A*0201 
D227K/T228A mutation, interferon (IFN)-γ production by the 1E6 CD8+ T-cell clone was completely abrogated 
(Fig. 1A). Macrophage inflammatory protein (MIP)-1β release was similarly compromised at physiologically 
relevant peptide concentrations (Fig. 1B).
Next, we performed similar experiments with the CD8+ T-cell clone ALF8, which recognises the 
HLA-A*0201-restricted influenza A virus matrix protein (M1) epitope GILGFVFTL. The ALF8 TCR engages 
cognate pMHCI with a monomeric affinity (KD = 7.71 μ M; Table 1 and Supplementary Fig. S1) that falls within 
the typical range for pathogen-specific TCRs (KD = 1–50 μ M)3,26. ALF8 exhibited functional responses at sub-
stantially lower concentrations of exogenous peptide compared with 1E6. In the absence of an intact pMHCI/
CD8 interaction, ALF8 was still capable of efficient production of IFN-γ and MIP-1β , even at low peptide concen-
trations (Fig. 1C,D). Similar results were obtained with the CD8+ T-cell clone MCNLV, which is specific for the 
HLA-A*0201-restricted human cytomegalovirus (HCMV) pp65 epitope NLVPMVATV (Fig. 1E,F). These data 
suggest that autoreactive CD8+ T-cells expressing low affinity TCRs are less antigen sensitive and more dependent 
on CD8 coreceptor engagement as compared to pathogen-specific CD8+ T-cells.
CD8 has a profound effect on the number of peptides that can be recognised by autoreactive 
CD8+ T-cells. In an earlier study, we showed that the 1E6 clone is highly cross-reactive in the context of 
HLA-A*0201, recognising ~1 million different peptide ligands at physiologically relevant concentrations40. As 
part of this earlier study we performed a 10mer combinatorial peptide library (CPL) scan of the 1E6 clone using 
C1R-A*0201 targets (WT MHCI/CD8) to present each peptide mixture40. To extend these findings, we performed 
a 10mer combinatorial peptide library (CPL) scan of 1E6 using C1R-A*0201 D227K/T228A targets (Null MHCI/
CD8) (Fig. 2 and Supplementary Fig. S2). The 1E6 clone is highly promiscuous in the presence of an intact 
pMHCI/CD8 interaction (Fig. 2). However, in the absence of CD8 engagement, very few responses were observed 
(Fig. 2 and Supplementary Fig. S2). This is consistent with a previous study that demonstrates that CD8 can con-
trol levels of T-cell crossreactivity34. Abrogation of the pMHCI/CD8 interaction eliminates promiscuous pMHCI 
recognition of the 1E6 TCR.
Selection of a potent anti-CD8 antibody that blocks pMHCI tetramer binding at low TCR/pMHCI 
affinities. It is established that anti-CD8 antibodies display various phenotypes35,37. In particular, SK1 and 
DK25 can be classified as blocking anti-CD8 antibodies because they inhibit pMHCI binding at the cell sur-
face. Consistent with this trait, both SK1 and DK25 blocked pMHCI tetramer staining of the 1E6 clone in a 
concentration-dependent manner (Fig. 3A,B). In contrast, pMHCI tetramer staining of the ALF8 clone was min-
imally disrupted by the same antibodies across an identical concentration range (Fig. 3C,D). These results suggest 
that anti-CD8 antibody-mediated blockade of pMHCI binding occurs selectively in the presence of a weak TCR/
www.nature.com/scientificreports/
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pMHCI interaction. Further experiments designed to extend this observation were conducted with DK25, which 
exhibited more potent blocking activity in side-by-side comparisons with SK1 (Fig. 3A–D).
DK25 blocks the activation of CD8+ T-cells at low TCR/pMHCI affinities. To test the hypothesis that 
DK25 can be used as a selective agent to target CD8+ T-cells bearing low affinity TCRs, we again employed the 
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Figure 1. Autoreactive CD8+ T-cells expressing low affinity TCRs are highly CD8-dependent. 6 × 104 
C1R-A*0201 (WT MHCI/CD8) or C1R-A*0201 D227K/T228A (Null MHCI/CD8) target cells were pulsed 
with cognate peptide at the indicated concentrations in duplicate for 1 hour at 37 °C. 3 × 104 clonal 1E6 (A,B), 
ALF8 (C,D) or MCNLV (E,F) CD8+ T-cells were then added and the plates were incubated for 4 hours at 37 °C. 
Supernatants were assayed for IFN-γ and MIP-1β by ELISA. The mean ± SD of two replicate assays is shown. 
Data is representative of three independent experiments.
TCR KDeq (μM) kon (104/Ms) koff (1/s) KDcalc (μM) t1/2 (s)
ALF3 5.84 ± 0.10 2.19 ± 0.44 0.128 ± 0.007 7.33 ± 0.40 7.8
ALF8 7.71 ± 0.17 2.89 ± 0.29 0.158 ± 0.005 5.48 ± 0.39 6.3
Table 1.  Affinities and kinetics of GILGFVFTL-HLA-A*0201 binding to the ALF3 and ALF8 TCRs. KDeq is the 
measured equilibrium affinity, kon is the association rate, koff is the dissociation rate, t1/2 is the half-life (0.693/koff) 
and KDcalc is the calculated affinity based on kinetic parameters.
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Figure 2. CD8 has a profound effect on the number of peptides that can be recognised by the diabetogenic 
CD8+ T-cell clone 1E6. 6 × 104 C1R-A*0201 (WT MHCI/CD8) or C1R-A*0201 D227K/T228A (Null MHCI/
CD8) target cells were pulsed in duplicate with each mixture from a 10mer combinatorial peptide library 
(100 μ M) for 2 hours at 37 °C. 3 × 104 clonal 1E6 CD8+ T-cells were then added and the plates were incubated 
overnight at 37 °C. Supernatants were assayed for MIP-1β by ELISA. The primary screens with wildtype 
(WT) targets were reported previously40; the primary screens with D227K/T228A (Null) targets are shown 
in Supplementary Fig. S2. A box plot summary is presented with the index sequence at the bottom. Data is 
representative of two independent experiments.
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1E6 clone and examined activation in response to both the cognate ligand (ALW) and the altered peptide variant 
RQWGPDPAAV (RQW), which binds the 1E6 TCR with a substantially higher monomeric affinity (KD = 10 μ M)41. 
This monoclonal system allowed a rigorous evaluation of DK25-mediated effects as a function of a single variable 
parameter, namely the affinity of the TCR/pMHCI interaction. In cytotoxicity assays, the 1E6 clone killed target 
cells presenting either ALW or RQW at levels proportional to the corresponding TCR/pMHCI affinities (Fig. 4A). 
This is consistent with a recent publication that demonstrates a strong correlation between 1E6 T-cell antigen 
sensitivity and TCR/pMHCI affinity42. Interestingly, there is no correlation between ligand potency and pMHCI 
stability in this system (Tm for A2-ALW and A2-RQW was 60 °C and 54 °C, respectively)42. The addition of DK25 
at low concentrations (0.5 or 1 μ g/ml) abolished the killing response to target cells presenting ALW (Fig. 4B). In 
contrast, the same concentrations of DK25 failed to abolish 1E6-mediated killing of target cells presenting RQW 
(Fig. 4C). These data suggest that DK25 selectively inhibits CD8+ T-cell activation in the presence of low affinity 
TCR/pMHCI interactions.
DK25 selectively blocks autoreactive CD8+ T-cell activation. Next, we evaluated the ability of DK25 
to inhibit autoreactive and pathogen-specific CD8+ T-cell clones in parallel activation assays. Complete block-
ade of MIP-1β release by the 1E6 clone in response to the cognate peptide ALW was observed in the presence of 
DK25 at all concentrations tested (0.25, 0.5 and 1 μ g/ml; Fig. 5A). In contrast, the same concentrations of DK25 
minimally impacted the activation of ALF3, a CD8+ T-cell clone specific for the HLA-A*0201-restricted influenza 
A virus M1 epitope GILGFVFTL (Fig. 5D). Consistent with this observation, the ALF3 TCR engaged cognate 
pMHCI with a high monomeric affinity (KD = 5.84 μ M; Table 1 and Supplementary Fig. S1).
We conducted similar experiments across a range of different epitope specificities and HLA class I restriction 
elements. The autoreactive CD8+ T-cell clones 3F2 and 4C6 recognise the HLA-A*0201-restricted PPI epitope 
ALW and the HLA-A*2402-restricted PPI epitope LWMRLLPLL, respectively. In both cases, MIP-1β release was 
completely inhibited by DK25 across all cognate peptide concentrations tested (Fig. 5B,C). The pathogen-specific 
CD8+ T-cell clones SB27 and MCNLV recognise the HLA-B*3508-restricted Epstein-Barr virus (EBV) BZLF1 
epitope LPEPLPQGQLTAY and the HLA-A*0201-restricted HCMV pp65 epitope NLVPMVATV, respectively. In 
both cases, robust peptide-specific activation was observed in the presence of DK25 (Fig. 5E,F). The SB27 TCR has 
been well characterised previously and binds cognate pMHCI with a high monomeric affinity (KD = 9.9 μ M)43,44. 
Comparable results were obtained for all clones in cytotoxicity assays (Fig. 6A–F). These differences in suscepti-
bility to inhibition by DK25, comparing grouped autoreactive versus pathogen-specific CD8+ T-cells, were sig-
nificant at the 5% level (Wilcoxon-Mann-Whitney rank sum test). Anti-CD8 antibodies can therefore be used to 
block the activation of autoreactive CD8+ T-cells in a selective manner regardless of epitope specificity or HLA 
class I restriction.
DK25 inhibits pancreatic β-cell killing by PPI-specific CD8+ T-cells. To examine the utility 
of anti-CD8 antibody-mediated blockade in a more physiological setting, we tested the ability of DK25 to 
Figure 3. Anti-CD8 antibodies can block pMHCI tetramer binding at low TCR/pMHCI affinities. 5 × 104 
clonal 1E6 (A,B) or ALF8 (C,D) CD8+ T-cells were pre-treated with or without the indicated anti-human CD8 
antibodies at various concentrations for 20 minutes at 4 °C and then stained with 25 μ g/ml of cognate pMHCI 
tetramer for 15 minutes at 37 °C. The column graphs depict percent maximal tetramer staining (A,C) or percent 
inhibition of tetramer staining (B,D). Data is representative of three independent experiments.
www.nature.com/scientificreports/
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inhibit pancreatic β -cell killing by the 1E6 clone. In preliminary experiments, we made use of the surrogate 
β -cell line K562-PPI-A*0201, created by transfecting K562 leukemia cells with PPI and HLA-A*0201. DK25 
blocked 1E6-mediated killing of K562-PPI-A*0201 cells at concentrations > 0.2 μ g/ml (Fig. 7A), consistent with 
the exogenous peptide titration data (Figs 5 and 6). We then performed a similar experiment using pancreatic 
β -cells from an HLA-A*0201+ donor (Fig. 7B). In the absence of DK25, pancreatic β -cells were readily killed 
by 1E6. The CD8+ T-cell clone NLV2, which was derived from a T1D patient as a control and recognises the 
HLA-A*0201-restricted HCMV pp65 epitope NLVPMVATV, displayed no direct lytic activity in the same assay. 
Pancreatic β -cell killing by 1E6 was inhibited by DK25 in a dose-dependent manner, reaching background levels 
at antibody concentrations ≥ 0.5 μ g/ml. In contrast, DK25 had no effect on the ability of NLV2 to kill cognate 
peptide-pulsed HLA-A*0201+ pancreatic β -cells. There was a highly significant dependence on DK25 concen-
tration for 1E6 killing of pancreatic β -cells (P-value = 0.0078), whereas the dependence on DK25 concentration 
for NLV2 was non-significant (NLV2 vs pancreatic β -cells: P = 0.52 and NLV2 vs NLV-pulsed pancreatic β -cells: 
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Figure 4. DK25 blocks the activation of CD8+ T-cells at low TCR/pMHCI affinities. 2 × 103 51Cr-labeled 
C1R-A*0201 target cells were peptide-pulsed with either ALWGPDPAAA (A,B) or RQWGPDPAAV (A,C) 
at the indicated concentrations for 1 hour at 37 °C. 1 × 104 clonal 1E6 CD8+ T-cells were then added with 
or without the anti-human CD8 antibody DK25 at a final concentration of 0.5 or 1 μ g/ml. Cytotoxicity was 
determined after 4 hours as described in the Materials and Methods. The mean ± SD of three replicate assays is 
shown. Data is representative of three independent experiments.
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P = 0.28). Therefore, relatively low concentrations of DK25 can therefore be used to inhibit CD8+ T-cell-mediated 
pancreatic β -cell destruction without impacting pathogen-specific immunity.
DK25 efficiently blocks the activation of myelin-specific CD8+ T-cells. To extend our study to other 
autoimmune targets, we examined the effect of DK25 on the activation of BW58 cells expressing human CD8α 
β and the 2D1 TCR, which is specific for the HLA-A*0301-restricted myelin proteolipid protein (PLP) epitope 
KLIETYFSK. The 2D1 TCR plays a role in the induction of a multiple sclerosis-like disease in humanised mice 
expressing HLA-A*030145. DK25 efficiently blocked peptide-induced interleukin (IL)-2 production by the BW58 
cell line at concentrations of 0.5 and 1 μ g/ml (Fig. 8A,B). Incomplete but nonetheless potent suppression was 
observed at an antibody concentration of 0.25 μ g/ml. Anti-CD8 antibody-mediated blockade of autoreactive 
CD8+ T-cells is therefore not restricted by tissue specificity.
Blocking anti-mouse CD8 antibodies inhibit autoreactive CD8+ T-cell activation. Two previous 
studies have used anti-CD8 antibodies to prevent and reverse TID in mice20,21. In both cases, the investigators 
relied principally on the anti-mouse CD8 antibody YTS105.18. Shore et al. demonstrated that YTS105.18 does 
not block pMHCI tetramer binding or CD8+ T-cell activation38. We confirmed this observation by showing that 
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Figure 5. DK25 selectively blocks autoreactive CD8+ T-cell activation. 6 × 104 C1R-A*0201 target cells 
were peptide-pulsed with ALWGPDPAAA (A,B), GILGFVFTL (D) or NLVPMVATV (F) at the indicated 
concentrations for 1 hour at 37 °C. In parallel, 6 × 104 K562-A*2402 or C1R-B*3508 target cells were peptide-
pulsed similarly with LWMRLLPLL (C) or LPEPLPQGQLTAY (E), respectively. 3 × 104 clonal 1E6 (A), 3F2 
(B), 4C6 (C), ALF3 (D), SB27 (E) or MCNLV (F) CD8+ T-cells pre-treated for 30 minutes at 37 °C with the 
anti-human CD8 antibody DK25 at the indicated concentrations were then added and the plates were incubated 
for 4 hours at 37 °C. Supernatants were assayed for MIP-1β by ELISA. The mean ± SD of two replicate assays is 
shown. Data is representative of two independent experiments.
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murine CD8+ T-cells expressing the G9C8 TCR, which is specific for the H-2Kd-restricted insulin B chain epitope 
LYLVCGERG, exhibit robust activation in the presence of YTS105.18 (Fig. 9A). The blocking approach presented 
in this study is therefore distinct from the phenomena described in these earlier reports.
Next, we tested the anti-mouse CD8 antibody CT-CD8a, which inhibits pMHCI tetramer binding and CD8+ 
T-cell activation35,37. The G9C8 TCR binds cognate pMHCI with a low monomeric affinity (KD = 286 μ M)46. 
In line with our observations in human systems, CT-CD8a efficiently blocked peptide-induced activation of 
G9C8-expressing CD8+ T-cells (Fig. 9B). However, CT-CD8a cannot be used therapeutically in vivo because it 
triggers non-specific CD8+ T-cell activation with exposure times ≥ 18 hours37. To date, it has not been possible 
to identify a blocking anti-mouse CD8 antibody with a phenotype akin to DK25, which may be due to intrinsic 
biophysical and structural differences between mice and humans with respect to the pMHCI/CD8 interaction47.
Discussion
Over the past decade, a substantial body of evidence has accumulated to implicate CD8+ T-cells as key play-
ers in the pathogenesis of common autoimmune diseases such as T1D14–16,48,49, MS17,20,50 and psoriasis51. 
Autoreactive TCRs typically engage cognate pMHCI with low monomeric affinities (KDs > 100 μ M), in contrast 
to pathogen-specific TCRs (KDs ~1–50 μ M)26. It is also established that CD8+ T-cells expressing low affinity TCRs 
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Figure 6. DK25 selectively blocks autoreactive CD8+ T-cell killing. 2 × 103 51Cr-labeled C1R-A*0201 
(A,B,D,F), K562-A*2402 (C) or C1R-B*3508 (E) target cells were peptide-pulsed with ALWGPDPAAA 
(A,B), LWMRLLPLL (C), GILGFVFTL (D), LPEPLPQGQLTAY (E) or NLVPMVATV (F) at the indicated 
concentrations for 1 hour at 37 °C. 1 × 104 clonal 1E6 (A), 3F2 (B), 4C6 (C), ALF3 (D), SB27 (E) or MCNLV (F) 
CD8+ T-cells were then added with or without the anti-human CD8 antibody DK25 at a final concentration of 
0.25, 0.5 or 1 μ g/ml. Cytotoxicity was determined after 4 hours as described in the Materials and Methods. The 
mean ± SD of three replicate assays is shown and is representative of two independent experiments.
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are strictly dependent on CD8 for ligand-induced activation33,34. These observations led us to hypothesise that 
CD8-targeted strategies could be used to block CD8+ T-cell-mediated autoreactivity in a selective manner.
In preliminary experiments, we tested this possibility using the well-characterised autoreactive CD8+ T-cell 
clone 1E6, which was isolated from a patient with T1D and displays potent reactivity against pancreatic β -cells39. The 
cognate epitope ALW is naturally processed from PPI and represents a major target for circulating effector CD8+ 
T-cells in HLA-A*0201+ patients with TID39. We found that peptide-induced activation of 1E6 is highly depend-
ent on CD8, consistent with the previously reported low affinity TCR/pMHCI interaction (KD = 278 μ M)31,32. 
It is also established that 1E6 is extremely cross-reactive in the context of HLA-A*0201, recognising ~1 million 
different peptide ligands at physiologically relevant concentrations40. In line with the strict requirement for CD8, 
we observed a substantial winnowing of ligand cross-recognition in the absence of an intact pMHCI/CD8 inter-
action. Based on these findings and the fact that pathogen-specific CD8+ T-cells displayed higher levels of func-
tional sensitivity and robust activation profiles irrespective of CD8 engagement, we explored the potential utility 
of CD8-specific antibodies as a means to block CD8+ T-cell activation selectively in response to self-derived 
peptides.
Previous work has shown that anti-CD8 antibodies exhibit diverse functional and phenotypic characteristics35,37. 
We selected the antibody clones SK1 and DK25 for further evaluation in view of the fact that they inhibit pMHCI 
tetramer binding and CD8+ T-cell activation in the absence of non-specific stimulatory effects. The blocking 
effect on pMHCI tetramer binding was concentration-dependent in both cases and only apparent at low TCR/
pMHCI affinities. The DK25 clone displayed greater efficacy in this regard and was therefore used in subsequent 
experiments.
To test the ability of DK25 to inhibit CD8+ T-cell activation as a function of TCR/pMHCI affinity, we utilised a 
monoclonal system in which an HLA-A*0201-restricted altered peptide ligand was used to generate a high affinity 
0 0.06 0.012 0.025 0.05 0.195 0.2 0.4 0.8 1.6
0
10
20
30
%
 S
pe
ci
fic
 ly
si
s
B
A
[DK25] µg/ml
0 0.1 0.5 1
0
20
40
60
80
100 1E6 clone vs islets
NLV2 clone vs islets
NLV2 clone vs NLV-pulsed islets
[DK25] µg/ml
%
K
illi
ng
0 0.06 0.012 0.025 0.05 0.195 0.2 0.4 0.8 1.6
0
10
20
30 E:T 1:1 
E:T 5:1 
Figure 7. DK25 inhibits pancreatic β-cell killing by autoreactive CD8+ T-cells. (A) 2 × 103 51Cr-labeled 
K562-PPI-A*0201 cells were peptide-pulsed with ALWGPDPAAA at a concentration of 10−5 M for 1 hour at 
37 °C. Clonal 1E6 CD8+ T-cells were then added at an E:T ratio of 1:1 (upper panel) or 5:1 (lower panel) with 
or without the anti-human CD8 antibody DK25 at the indicated concentrations. Cytotoxicity was determined 
after 4 hours as described in the Materials and Methods. The mean ± SD of three replicate assays is shown and 
is representative of three independent experiments. (B) 5 × 103 HLA-A*0201+ islet cells were incubated for 
4 hours with clonal 1E6 or NLV2 CD8+ T-cells pre-treated for 30 minutes at 37 °C with the anti-human CD8 
antibody DK25 at the indicated concentrations. As a control, islet cells were peptide-pulsed with NLVPMVATV 
at a concentration of 5 μ g/ml for 30 minutes at 37 °C. All data points represent the mean of triplicate evaluations 
at a final E:T ratio of 25:1. Islet cell killing was measured using a non-radioactive europium hydrophilic ligand 
assay as described in the Materials and Methods. Significance of the effect of DK25 was evaluated using linear 
regression and the t-test statistic as described in the materials and methods.
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interaction with the clonotypically-expressed 1E6 TCR. DK25 efficiently blocked activation of the 1E6 clone in 
response to the cognate ligand ALW, whereas only a marginal effect was observed with the altered peptide ligand 
Figure 8. DK25 inhibits the activation of myelin-specific CD8+ T-cells. 3 × 104 BW58 cells expressing 
human CD8α β and the 2D1 TCR were stimulated overnight at 37 °C in the presence of 6 × 104 KLIETYFSK 
peptide-pulsed HLA-A*0301+ B-LCL target cells with or without the anti-human CD8 antibody DK25 at a final 
concentration of 0.25, 0.5 or 1 μ g/ml (A,B). Supernatants were assayed for IL-2 by ELISA. The mean ± SD of two 
replicate assays is shown in (B) and is representative of three independent experiments.
Figure 9. CT-CD8a blocks the activation of autoreactive murine CD8+ T-cells. 6 × 104 P815 murine 
mastocytoma cells were peptide-pulsed with LYLVCGERG at the indicated concentrations for 1 hour at 37 °C. 
3 × 104 splenic G9C8 TCR-transgenic CD8+ T-cells pre-treated for 30 minutes at 37 °C with either the anti-mouse 
CD8 antibody YTS105.18 (A) or the anti-mouse CD8 antibody CT-CD8a (B) at the indicated concentrations 
were then added and the plates were incubated overnight at 37 °C. Supernatants were assayed for MIP-1β by 
ELISA. The mean ± SD of two replicate assays is shown and is representative of two independent experiments.
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RQW, which resembles a pathogen-derived epitope in terms of TCR/pMHCI affinity (KD = 10 μ M)3,41. Similar 
results were obtained across a panel of different autoreactive (1E6, 3F2 and 4C6) and pathogen-specific (ALF8, 
SB27 and MCNLV) CD8+ T-cell clones. These findings suggest that blocking anti-CD8 antibodies can be used 
as selective agents for therapeutic purposes in the setting of autoimmune disease. In support of this notion, we 
found that DK25 can prevent CD8+ T-cell-mediated destruction of pancreatic β -cells and block the activation 
of myelin-specific CD8+ T-cells. As such, further research is warranted into the utility of this approach in the 
treatment of CD8+ T-cell mediated autoimmunity. Although, it is important to note that more work is required 
to identify pMHCI antigens important in these diseases and assess the affinity of the TCRs that recognise them to 
understand the scope for this approach.
Previous studies have examined the ability of anti-CD8 antibodies to induce tolerance in murine models of 
TID20,21. However, the YTS105.18 antibody clone used for this purpose does not inhibit either pMHCI tetramer 
binding or peptide-induced CD8+ T-cell activation38. The tolerising effect of YTS105.18 is therefore distinct from 
the novel blocking strategy proposed here. In contrast, the CT-CD8a antibody displays an inhibitory pheno-
type in mice akin to SK1 and DK25 in humans35. Autoreactive murine CD8+ T-cells were highly susceptible to 
CT-CD8a-mediated blockade in vitro, but the presence of non-specific stimulatory effects after prolonged expo-
sure precluded confirmatory experiments in vivo37.
The next step will be to identify a suitable in vivo model to test the utility of this approach, to establish param-
eters such as optimal antibody concentration and assess the effect of targeting CD8 on the ability to mount an 
adequate pathogen specific response. The current literature suggests that during an acute response to path-
ogen, a broad range of TCR affinities are mobilised52. However, strong TCR ligation is required to sustain a 
T-cell response and as such, the TCR repertoire “matures” so that predominantly higher affinity TCRs remain52. 
Therefore, inhibiting the activation of low affinity pathogen-specific T-cells would not be anticipated to have a 
major impact on the ability to control infection as there would exist a degree of redundancy in the mobilised 
TCR repertoire, such that higher affinity TCRs would still be able to expand and control infection. Future in vivo 
work would also allow us to assess the possibility that autoreactive CD8+ T-cells with higher than expected TCR 
affinities (KDs < 100 μ M) occur in the repertoire and the impact that this may have on the effectiveness of this 
approach.
The DK25 antibody targets CD8α , which is expressed not only as a heterodimer with CD8β, exclusively on 
CD8+ T-cells, but also in homodimeric form on dendritic cells, natural killer cells and γ δ T-cells. Although the 
precise role of CD8α α is unclear, it is thought to act as a modulator of immune function53,54. The impact of chain 
specificity as a determinant of in vivo effects will therefore require further investigation as it is anticipated that 
antibodies which exclusively target the CD8α β heterodimer would be more desirable and associated with a more 
predictable outcome. The exact mechanism of anti-CD8 antibody action is still unclear35,37. In addition, the use 
of monoclonal antibodies as therapeutics is often not ideal because they can be costly to produce, can mediate 
side effects (via FcR binding) and require intravenous administration. Although F(ab’)2 fragments retain the 
same phenotype as the parental antibody, the overall magnitude of the affect can be reduced37. Therefore, a viable 
alternative would be to design small molecular inhibitors that block the interaction between pMHCI and CD8β .
Current treatments for autoimmune and inflammatory diseases often rely on the induction of profound 
and/or long-lasting immunosuppression55–57. However, adverse effects are common and often relate to a nega-
tive impact on protective immune responses. Our data suggest that autoreactive CD8+ T-cells can be preferen-
tially targeted using blocking anti-CD8 antibodies. Additional modalities could also be employed based on the 
underlying biology, such as rationally designed small molecular inhibitors and soluble versions of the inhibitory 
immunoglobulin-like transcript 2 (ILT2) receptor58. These approaches hold the potential to suppress pathogenic 
CD8+ T-cell-mediated autoimmunity without the attendant side effects that complicate standard therapeutic 
interventions.
Materials and Methods
Cells. The following CD8+ T-cell clones were used in this study: (i) 1E6 and 3F2, specific for the HLA-A*0201-
restricted PPI epitope ALWGPDPAAA (residues 15–24)39; (ii) ALF3 and ALF8, specific for the HLA-A*0201-
restricted influenza A virus M1 epitope GILGFVFTL (residues 58–66)37; (iii) MCNLV and NLV2, specific for 
the HLA-A*0201-restricted HCMV pp65 epitope NLVPMVATV (residues 495–503); (iv) 4C6, specific for 
the HLA-A*2402-restricted PPI epitope LWMRLLPLL (residues 3–11)59; and (v) SB27, specific for the HLA-
B*3508-restricted EBV BZLF1 epitope LPEPLPQGQLTAY (residues 52–64)60. Equilibrium binding affinities for 
the corresponding TCR/pMHCI interactions are shown in Table 2. C1R target cells expressing HLA-A*0201 
(C1R-A*0201), HLA-A*0201 D227K/T228A (C1R-A*0201 D227K/T228A) or HLA-B*3508 (C1R-B*3508) 
were generated as described previously61. K562 cells expressing HLA-A*2402 (K562-A*2402) and BW58 cells 
expressing human CD8α β and the 2D1 TCR, which is specific for the HLA-A*0301-restricted myelin PLP epitope 
KLIETYFSK (residues 45–53), were also described previously39,45. All CD8+ T-cells were maintained in RPMI 
1640 containing 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 10% heat-inactivated fetal 
calf serum (all Life Technologies) supplemented with 2.5% Cellkines (Helvetica Healthcare), 200 IU/ml IL-2 and 
25 ng/ml IL-15 (both PeproTech).
G9 transgenic mice. Transgenic mice expressing the G9C8 TCR on the NOD.TCRCα −/− genetic back-
ground were generated as described previously62,63. Mice were housed in microisolators or scantainers in the 
specific pathogen-free facility at Cardiff University. The G9C8 TCR is specific for the H-2Kd-restricted insulin B 
chain epitope LYLVCGERG (residues 15–23)62,64. All procedures were performed in accordance with protocols 
approved by the UK Home Office.
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Anti-CD8 antibodies. The following antibodies were used in this study: (i) APC-conjugated anti-human 
CD8α (DK25; DAKO); (ii) purified unconjugated anti-human CD8α (SK1; BD Biosciences); (iii) purified uncon-
jugated anti-mouse CD8α (CT-CD8a; Lifespan BioScience); and (iv) purified unconjugated anti-mouse CD8α 
(YTS105.18; Thermo Scientific).
CD8+ T-cell effector function assays. 6 × 104 C1R-A*0201, C1R-A*0201 D227K/T228A, C1R-B*3508, 
K562-A*2402 or HLA-A*0301+ B-lymphoblastoid cell line (B-LCL) targets were pulsed with various concen-
trations of cognate peptide as indicated for 1 hour at 37 °C. 3 × 104 clonal CD8+ T-cells pre-treated for 30 min-
utes at 4 °C with various concentrations of the anti-human CD8 antibody DK25 as indicated were incubated 
with peptide-pulsed targets for 4 hours at 37 °C. Untreated effectors and unpulsed targets were used as controls. 
Supernatants were harvested and assayed for IFN-γ and MIP-1β by ELISA (R&D Systems).
Combinatorial peptide library screens. A 10mer CPL in positional scanning format was purchased from 
Pepscan. CPL scans were performed as described previously40,65. Briefly, 6 × 104 C1R-A*0201 or C1R-A*0201 
D227K/T228A cells were pulsed with each of the 10mer CPL mixtures (100 μ M) in duplicate for 2 hours at 37 °C. 
3 × 104 clonal CD8+ T-cells were then added and the plates were incubated overnight at 37 °C. Supernatants were 
harvested and assayed for MIP-1β by ELISA (R&D Systems).
pMHCI tetramer staining. Soluble biotinylated pMHCI proteins were manufactured and tetramerised 
with fluorochrome-labeled streptavidin as described previously6. 5 × 104 clonal CD8+ T-cells pre-treated with 
or without the indicated anti-human CD8 antibodies at various concentrations in 20 μ l of PBS for 20 minutes at 
4 °C were stained with 25 μ g/ml of cognate pMHCI tetramer for 15 minutes at 37 °C. The cells were then washed 
and stained with LIVE/DEAD Fixable Aqua or Violet (Life Technologies) for 10 minutes at room temperature. 
Data were acquired using a FACSCantoII flow cytometer (BD Biosciences) and analysed with FlowJo software 
(TreeStar).
Chromium release assay. 2 × 103 C1R-A*0201, K562-A*2402 or C1R-B*3508 targets were labeled with 30 μ 
Ci of 51Cr per 106 cells for 1 hour at 37 °C in RPMI 1640 containing 100 U/ml penicillin, 100 mg/ml streptomycin, 
2 mM L-glutamine and 2% heat-inactivated fetal calf serum (all Life Technologies). Labeled targets were then 
pulsed with peptide for 1 hour at 37 °C. CD8+ T-cells pre-treated with or without the indicated anti-human CD8 
antibodies at various concentrations for 30 minutes at 4 °C were added at an effector-to-target (E:T) ratio of 5:1 
and the plates were incubated for 4 hours at 37 °C. Spontaneous release was determined using targets incubated 
alone. Total release was determined using targets incubated in the presence of 5% Triton X-100 (Sigma-Aldrich). 
For each sample, 10 μ l of supernatant was mixed with 150 μ l of OptiPhase Supermix Scintillation Cocktail (Perkin 
Elmer) and analysed using a MicroBeta TriLux Liquid Scintillation and Luminescence Counter (Perkin Elmer). 
Specific lysis was calculated using the following formula:
− − × .(experimental release spontaneous release/total release spontaneous release) 100
Human islet killing assays. Human islet isolations were performed as described previously using pancre-
ata retrieved with the consent of donors’ relatives and permission from the Ethical Review Committee of King’s 
College Hospital66. Islet cells were cultured in monolayers for 16–24 hours with medium containing 16 μ mol 
glucose plus IL-1β (50 IU/ml; Strathmann Biotec), tumor necrosis factor (TNF)-α (2500 IU/ml; Miltenyi Biotec), 
IFN-γ (500 IU/ml; Miltenyi Biotec) and IFN-α (1000 IU/ml; Roche Laboratories) to increase MHCI expression39. 
Clonal CD8+ T-cells pre-treated for 30 minutes at 37 °C with various concentrations of the anti-human CD8 
antibody DK25 as indicated were then incubated with 5 × 103 islet cell targets at an E:T ratio of 25:1 for 4 hours 
at 37 °C. Cytotoxicity was analysed using a non-radioactive europium hydrophilic ligand assay with DELFIA 
Technology (Perkin Elmer)39,67.
Protein expression, purification and surface plasmon resonance. The ALF3 and ALF8 TCRs 
were expressed, refolded and purified using an engineered disulfide linkage between the α and β constant 
domains68. Soluble HLA-A*0201 incorporating the influenza A virus M1 peptide GILGFVFTL was prepared 
as described previously69. All surface plasmon resonance experiments were conducted at 25 °C using a BIAcore 
3000 instrument with HBS buffer (10 mM HEPES pH 7.4, 150 mM NaCl and 0.005% surfactant P20) containing 
1% BSA to prevent non-specific binding. The human TCR-specific monoclonal antibody 12H870, which recog-
nises a conformation-dependent epitope, was amine-coupled to research-grade CM5 chips. Ligand binding to 
TCR Specificity
HLA 
restriction Minimal epitope KDeq (μM)
1E6 PPI A*0201 ALWGPDPAAA 27831,32
1E6 PPI A*0201 RQWGPDPAAV 1041
3F2 PPI A*0201 ALWGPDPAAA > 25073
4C6 PPI A*2402 LWMRLLPLL 10073
SB27 EBV B*3508 LPEPLPQGQLTAY 9.943,44
Table 2.  Measured TCR/pMHCI equilibrium binding affinities (KDeq) for the CD8+ T-cell clones used in 
this study.
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solid-phase TCRs was then measured over a pMHCI concentration range of 0.78–200 μ M according to estab-
lished protocols68. Data were analysed using BIAevaluation software version 3.1 with the 1:1 Langmuir binding 
model.
Statistical analysis. DK25-induced shifts in functional sensitivity were quantified by calculating differences 
in pEC50 (delta pEC50), a parameter determined as − log [50% maximal response peptide concentration] for each 
condition (Supplementary Table 1)71. Differences in susceptibility to inhibition by DK25, comparing grouped 
autoreactive versus pathogen-specific CD8+ T-cells, were assessed using the Wilcoxon-Mann-Whitney rank sum 
test72. The effect of DK25 in pancreatic islet experiments was assessed using linear regression and the t-test statis-
tic with built-in tools in Mathematica72.
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